drugset / Trial / NCT02236988

Study to Evaluate Pharmacokinetics of Prototype Modified-Release Formulations Of Apremilast in Healthy Men

NCT02236988

Phase 1 Completed 80 enrolled Amgen
RandomizedCrossoverOpen-labelOther

Summary

This study will assess up to 12 different oral formulations of apremilast to determine how much apremilast is absorbed by the body compared to a reference formulation.

Timeline

Start
2014-01-07
Primary completion
2014-09-11
Completion
2014-09-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Apremilast Small molecule 30 mg Oral
Subject Apremilast Small molecule 75 mg Oral
Subject Apremilast Small molecule 80 mg Oral

Indications

No indication recorded.